HeartMate 3 LVAD is Leading Innovation in Left Ventricular Assist Devices
LVAD Advanced Care for Heart Failure Patients
The HeartMate 3™ LVAD, a mechanical circulatory support pump with Full MagLev™ Flow Technology has significantly advanced the field of LVAD treatment and therapy, setting the standard with innovation and outstanding clinical outcomes that make a meaningful difference in your patients’ lives.1
- The LVAD innovation includes Full MagLev Flow Technology in the pump which maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.1
- The HeartMate 3 LVAD is used for advanced heart failure patients needing short- or long-term mechanical circulatory support.
- The HeartMate 3 LVAD demonstrates proven long-term success in clinical use, supported by high survival rates and durable performance in pivotal studies such as MOMENTUM 3.¹
Extend Meaningful Survival With the HeartMate 3 LVAD
Join our email list to receive:
- The latest LVAD clinical data
- Patient selection
- HeartMate 3 case studies
- Clinician education
Clinical Outcomes made possible by Full MagLev Flow Technology
HeartMate 3 LVAD’s Full MagLev Flow Technology maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.
- Fully levitated, self-centering rotor that does not require hydrodynamic or mechanical bearings
- Large, consistent blood flow pathways to reduce shear stress3
- Intrinsic pulsatility to reduce stasis and minimize thrombus3,4
- The centrifugal pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood flow paths and a supplemental pulse
Benefits and Outcomes with HeartMate 3 LVAD
The HeartMate 3 LVAD delivers meaningful benefits for patients and clinicians managing advanced heart failure.
- Improved quality of life: Clinical evidence shows HeartMate 3 LVAD therapy can help relieve heart-failure symptoms, allowing patients to participate in more daily activities.1
- Proven survival advantage: Studies demonstrate higher long-term survival rates compared with medical therapy in appropriately selected patients.5
- Low complication rates: Full MagLev™ Flow Technology promotes gentle blood handling to minimize hemocompatibility-related adverse events.3
- Versatile treatment pathways: HeartMate 3 LVAD can be used as a bridge-to-transplant, bridge-to-recovery, or destination therapy option for advanced heart-failure management.
These outcomes underscore the role of HeartMate 3 LVAD in improving care for advanced-stage heart-failure patients while supporting clinicians in achieving long-term treatment success.
HeartMate 3 LVAD Resources
See how LVAD therapy can assist your late-stage heart failure patients. Download the HeartMate 3 LVAD data summary and patient referral guide to learn about the left ventricular assist device's clinical data supporting its efficacy and when to refer for an advanced heart failure evaluation.
References
- Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
- Abbott data on file.
- Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375- 383.
- Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.
- Sami F, Acharya P, Noonan G, et al. Palliative inotropes in advanced heart failure: comparing outcomes between milrinone and dobutamine. J Card Fail. 2022;28(12):1683 -1691
MAT-2012365 v6.0